DUBLIN, September 15, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth" report to their offering.
Over the 2015-2022 forecast period, the South-East Asia T2DM therapeutics market is expected to increase in value at a CAGR of 7.1%, from $1.7 billion to over $2.7 billion.
Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 states that as well as the rapidly expanding prevalence population in South-East Asia, market growth will be driven by the increased uptake of recently approved and emerging branded T2DM therapeutics, in favor of lower-cost generic products.
One of the publishers analysts states that: Unmet needs relating to patient convenience and ease of use will be addressed significantly over the forecast period. Higher levels of innovation are apparent in the early-stage pipeline, which may lead to considerable improvements beyond the existing range of products, in terms of safety and efficacy in the long term.
In terms of recently approved therapeutics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors have already achieved strong market uptake and are all expected to increase their market shares over the forecast period. In comparison with many previously marketed therapies, these new products provide improved weight control and lowered hypoglycemia risk.
In terms of late-stage pipeline products with the potential to change the treatment paradigm, six candidates stand out as offering superior safety, efficacy, and patient compliance. These are Novo Nordisk's NN-9535 (semaglutide subcutaneous formulation) and OG-217SC (semaglutide oral formulation) and Eli Lilly's Trulicity (dulaglutide), which are GLP-1 receptor agonists; Merck's ertugliflozin and Theracos's bexagliflozin, which are SGLT-2 inhibitors; and Merck's omarigliptin, which is a DPP-4 inhibitor.
Key Topics Covered:
1 Tables & Figures
3 Marketed Products
3.5 GLP-1 Receptor Agonists
3.6 DPP-4 Inhibitors
3.7 SGLT-2 Inhibitors
3.8 Insulin Therapies
3.9 Comparative Efficacy and Safety of Marketed Products
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Candidates
4.5 Comparative Efficacy and Safety of Pipeline Products
4.6 Product Competitive Framework
5 Clinical Trial Analysis
7 Market Dynamics, (Drivers and Barriers)
7.1.1 Aging Population, Increasing Obesity and Growing Economy
7.1.2 Increasing Awareness of T2DM
7.1.3 Continued Uptake of Recently Approved Drug Classes
7.1.4 Promising Late-Stage Pipeline Products can Change the Treatment Paradigm
7.1.5 Enhanced Usage of Combination Therapies
7.2.1 Non-pharmacological First-line Treatment
7.2.2 Widespread Usage of Generic Drugs
7.2.3 Poor Adherence to Treatment Regimens
7.2.4 Generic Erosion Resulting from Patent Expirations
8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.2 Co-development Deals
For more information about this report visit http://www.researchandmarkets.com/research/xcd43d/type_2_diabetes
Related Topics: Endocrine and Metabolic Disorder Drugs, Endocrinology
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets